SCHEMBL22372628

SCHEMBL22372628

CC(=O)N1C[C@H](OC(C)(C)C)C[C@H]1COC(C)C

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18513346 0.84 ATM (0.33) —
SCHEMBL25492845 0.84 MMP2 (0.33) —
SCHEMBL22996017 0.84 MMP2 (0.33) —
SCHEMBL24375001 0.84 ATM (0.33) —
SCHEMBL23710651 0.82 HCRTR2 (0.35) —
SCHEMBL18513313 0.82 HCRTR2 (0.35) —
SCHEMBL24098413 0.81 HCRTR2 (0.31) —
SCHEMBL24646128 0.80 — —
SCHEMBL23136552 0.80 HCRTR2 (0.32) —
SCHEMBL18972588 0.78 ATM (0.45) —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220324900-A1 COMPOSITIONS AND METHODS FOR MODULATING ANGIOPOIETIN-LIKE 3 EXPRESSION IONIS PHARMACEUTICALS, INC. (US) 2022-10-13 — — US disclosed
US-20200270609-A1 Single-Stranded RNAI Oligonucleotides Targeting APOC-III IONIS PHARMACEUTICALS, INC. (US) 2020-08-27 — — US disclosed
Send feedback